ClinicalTrials.gg
CompletedNCT05250063OraGrowtH213Updated May 15, 2026Results posted

Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)

A Phase 2 interventional study of LUM-201 in Growth Hormone Deficiency, sponsored by Lumos Pharma. Completed at 10 sites in 2 countries. Open to participants aged 3 Years to 13 Years. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Lumos Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
3 Years to 13 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 89 studies in Dwarfism, Pituitary with a site in United States — 11 open to participants now, 12 under way, 3 of them phase 3. Dwarfism, Pituitary · United States.

Enrollment
56th of 66
15 · median 49
Started
2022
the only one that year
Phase 2
15 of 89
3 open now
Registered
81st of 89
by date
Lead sponsor
4 of 89
Lumos Pharma

Among the 89 studies in Dwarfism, Pituitary with a site in United States, this one is the 56th largest by enrollment of the 66 interventional ones that give a count, is the only one that started in 2022, is one of 15 in phase 2, and was the 81st registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

11 of the 89 studies in Dwarfism, Pituitary with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 3 Years to 13 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Dwarfism, Pituitary with a site in United States, or all of them as a file.
02

Study summary

This is a multi-national trial. The goals of the trial are to study the growth response to LUM-201 administration in children with idiopathic growth hormone deficiency (GHD) previously treated with daily rhGH for 12 months in the LUM-201-01 trial.

Read the detailed description

This trial will have one screening/baseline visit with tests to assess if subjects are eligible to start study therapy. The screening/baseline visit can coincide with the Month 12 visit in the LUM-201-01 trial. Subjects will receive the same dose of LUM-201 as a daily oral dose each morning. LUM-201 will be adjusted for body weight increments at each clinic visit, as applicable.

The trial consists of 12 months of treatment. After screening, subjects will return to the clinic for 5 visits. During four of these clinic visits, safety laboratory samples will be collected.

03

Conditions studied

  • Growth Hormone Deficiency

Browse trials for

Keywords

  • LUM-201
  • PGHD
  • Height
  • Oral
04

Who can participate

Ages eligible
3 Years to 13 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parent/caregiver must sign the , and the subject must sign the assent, as applicable.
  • Must have previously completed 12 months of daily rhGH treatment as part of the LUM-201-01 PGHD trial.
  • Is eligible for study participation as confirmed by the principal investigator (PI)

Exclusion criteria

Exclusion Criteria:

  • Has a medical condition that, in the opinion of the PI and/or MM, adds unwarranted risk to use of LUM-201.
  • Uses any medication that, in the opinion of the PI and/or MM, can independently cause short stature or limit the response to exogenous growth factors.
  • Has planned or is receiving current long-term treatment with medications known to act as substrates, inducers, or inhibitors of the cytochrome system that metabolizes LUM-201
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    LUM-201 (3.2 mg/kg/day)

    Drug: LUM-201

Interventions

  • Administered orally once daily

06

What researchers measure

Primary outcomes

  1. Annualized Height Velocity (AHV) Measured as Standing Height With Stadiometer

    Mean change from day 1 to month 12, Annualized Height Velocity (AHV) Height is measured in triplicate, by a calibrated stadiometer and taking the mean value AVH equation is (h2-h1/t2-t1)\*365.25; h1 = height measured at day 1 h2 = height measured at month 12 t1 = day 1 t2 = month 12

    Time frame: Day 1 to Month 12

Secondary outcomes

  1. Occurrence of Adverse Events in Children With Growth Hormone Deficiency (GHD)

    Number of events

    Time frame: Day 1 to Month 12

  2. Growth Hormone (GH) Values

    Mean GH Values change from Day 1 to month 12 (Pre-Dose and 1 hour Post-Dose)

    Time frame: Day 1 to Month 12

  3. Insulin-Like Growth Factor 1 (IGF-1) Values

    Mean change from Day 1 to month 12 (IGF-1 Values Pre-Dose)

    Time frame: Day 1 to Month 12

  4. Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) Values

    Mean change from day 1 to month 12 (IGFBP-3 Values Pre-Dose)

    Time frame: Day 1 to Month 12

  5. Height (HT) Standard Deviation Score (SDS)

    Mean change from day 1 to month 12 in HT-SDS

    Time frame: Day 1 to Month 12

  6. Change in Weight

    Mean change in Weight from day 1 to month 12

    Time frame: Day 1 to Month 12

  7. Change in Weight - Standard Deviation Score (SDS)

    Mean change in Weight-SDS from day 1 to month 12

    Time frame: Day 1 to Month 12

  8. Change in Body Mass Index (BMI)

    Mean change from day 1 to month 12 in BMI

    Time frame: Day 1 to Month 12

  9. Change in Body Mass Index (BMI) - Standard Deviation Score (SDS)

    Mean change from Day 1 to month 12 in BMI-SDS

    Time frame: Day 1 to Month 12

  10. Change in Bone Age

    Mean change from day 1 to month 6 in bone age, measured by X-ray of left hand and wrist using Greulich \& Pyle atlas

    Time frame: Month 6

  11. Insulin-Like Growth Factor 1 (IGF-1) - Standard Deviation Score (SDS)

    Mean Change from day 1 to month 12 for IGF-1 - SDS Pre-dose Values

    Time frame: Day 1 to Month 12

07

Results

Posted Apr 13, 2026

Participant flow

Participant flow — Overall Study
MilestoneLUM-201 (3.2 mg/kg/Day)
Started15
Completed13
Not completed2

Outcome measures

PrimaryAnnualized Height Velocity (AHV) Measured as Standing Height With Stadiometer

Mean change from day 1 to month 12, Annualized Height Velocity (AHV) Height is measured in triplicate, by a calibrated stadiometer and taking the mean value AVH equation is (h2-h1/t2-t1)\*365.25; h1 = height measured at day 1 h2 = height measured at month 12 t1 = day 1 t2 = month 12

Time frame:
Day 1 to Month 12
Reported as:
Mean · cm/year
Annualized Height Velocity (AHV) Measured as Standing Height With Stadiometer
cm/yearLUM-201 (3.2 mg/kg/Day)
Annualized Height Velocity (AHV) Measured as Standing Height With Stadiometer0.098 ± 0.775
SecondaryOccurrence of Adverse Events in Children With Growth Hormone Deficiency (GHD)

Number of events

Time frame:
Day 1 to Month 12
Reported as:
Number · occurences
Occurrence of Adverse Events in Children With Growth Hormone Deficiency (GHD)
occurencesLUM-201 (3.2 mg/kg/Day)
Occurrence of Adverse Events in Children With Growth Hormone Deficiency (GHD)42
SecondaryGrowth Hormone (GH) Values

Mean GH Values change from Day 1 to month 12 (Pre-Dose and 1 hour Post-Dose)

Time frame:
Day 1 to Month 12
Reported as:
Mean · ng/ml
Growth Hormone (GH) Values
ng/mlLUM-201 (3.2 mg/kg/Day)
Month 12, Pre-Dose-0.05 ± 0.68
Month 12, 1 hour Post-Dose1.17 ± 2.81
SecondaryInsulin-Like Growth Factor 1 (IGF-1) Values

Mean change from Day 1 to month 12 (IGF-1 Values Pre-Dose)

Time frame:
Day 1 to Month 12
Reported as:
Mean · nmol/L
Insulin-Like Growth Factor 1 (IGF-1) Values
nmol/LLUM-201 (3.2 mg/kg/Day)
Insulin-Like Growth Factor 1 (IGF-1) Values-8.75 ± 14.59
SecondaryInsulin-Like Growth Factor Binding Protein 3 (IGFBP-3) Values

Mean change from day 1 to month 12 (IGFBP-3 Values Pre-Dose)

Time frame:
Day 1 to Month 12
Reported as:
Mean · nmol/L
Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) Values
nmol/LLUM-201 (3.2 mg/kg/Day)
Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) Values-58.033 ± 33.092
SecondaryHeight (HT) Standard Deviation Score (SDS)

Mean change from day 1 to month 12 in HT-SDS

Time frame:
Day 1 to Month 12
Reported as:
Mean · Standard Deviation Score
Height (HT) Standard Deviation Score (SDS)
Standard Deviation ScoreLUM-201 (3.2 mg/kg/Day)
Height (HT) Standard Deviation Score (SDS)0.08229 ± 0.20574
SecondaryChange in Weight

Mean change in Weight from day 1 to month 12

Time frame:
Day 1 to Month 12
Reported as:
Mean · kg
Change in Weight
kgLUM-201 (3.2 mg/kg/Day)
Change in Weight4.19 ± 1.74
SecondaryChange in Weight - Standard Deviation Score (SDS)

Mean change in Weight-SDS from day 1 to month 12

Time frame:
Day 1 to Month 12
Reported as:
Mean · Standard Deviation Score
Change in Weight - Standard Deviation Score (SDS)
Standard Deviation ScoreLUM-201 (3.2 mg/kg/Day)
Change in Weight - Standard Deviation Score (SDS)0.62279 ± 0.30934
SecondaryChange in Body Mass Index (BMI)

Mean change from day 1 to month 12 in BMI

Time frame:
Day 1 to Month 12
Reported as:
Mean · kg/m^2
Change in Body Mass Index (BMI)
kg/m^2LUM-201 (3.2 mg/kg/Day)
Change in Body Mass Index (BMI)0.969 ± 0.695
SecondaryChange in Body Mass Index (BMI) - Standard Deviation Score (SDS)

Mean change from Day 1 to month 12 in BMI-SDS

Time frame:
Day 1 to Month 12
Reported as:
Mean · Standard Deviation Score
Change in Body Mass Index (BMI) - Standard Deviation Score (SDS)
Standard Deviation ScoreLUM-201 (3.2 mg/kg/Day)
Change in Body Mass Index (BMI) - Standard Deviation Score (SDS)0.32057 ± 0.30768
SecondaryChange in Bone Age

Mean change from day 1 to month 6 in bone age, measured by X-ray of left hand and wrist using Greulich \& Pyle atlas

Time frame:
Month 6
Reported as:
Mean · year
Change in Bone Age
yearLUM-201 (3.2 mg/kg/Day)
Change in Bone Age2.01 ± 0.81
SecondaryInsulin-Like Growth Factor 1 (IGF-1) - Standard Deviation Score (SDS)

Mean Change from day 1 to month 12 for IGF-1 - SDS Pre-dose Values

Time frame:
Day 1 to Month 12
Reported as:
Mean · Standard Deviation Score
Insulin-Like Growth Factor 1 (IGF-1) - Standard Deviation Score (SDS)
Standard Deviation ScoreLUM-201 (3.2 mg/kg/Day)
Insulin-Like Growth Factor 1 (IGF-1) - Standard Deviation Score (SDS)-1.1083 ± 1.1529

Adverse events

Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LUM-201 (3.2 mg/kg/Day)0/15 (0%)0/15 (0%)13/15 (86.7%)
Most frequent other events
Showing 10 of 25
Most frequent other events
EventLUM-201 (3.2 mg/kg/Day)
Upper respiratory tract infectionsInfections and infestations3/15
InfluenzaInfections and infestations2/15
PharyngitisInfections and infestations2/15
Increased appetiteMetabolism and nutrition disorders2/15
EpistaxisRespiratory, thoracic and mediastinal disorders2/15
RashSkin and subcutaneous tissue disorders2/15
Abdominal pain upperGastrointestinal disorders1/15
PyrexiaGeneral disorders1/15
Drug hypersensitivityImmune system disorders1/15
BronchitisInfections and infestations1/15

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)LUM-201 (3.2 mg/kg/Day)
<=18 years15
Between 18 and 65 years0
>=65 years0
Age, Continuous
Age, Continuous(months)LUM-201 (3.2 mg/kg/Day)
Mean102 ± 25.5
Sex: Female, Male
Sex: Female, Male(Participants)LUM-201 (3.2 mg/kg/Day)
Female6
Male9
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LUM-201 (3.2 mg/kg/Day)
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White14
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)LUM-201 (3.2 mg/kg/Day)
United States9
Poland6
Baseline Height-Standard Deviation Score (SDS)
Baseline Height-Standard Deviation Score (SDS)(Height-SDS)LUM-201 (3.2 mg/kg/Day)
Mean-1.32492 ± 0.37944
Baseline Insulin-like growth factor 1 (IGF-1) SDS
Baseline Insulin-like growth factor 1 (IGF-1) SDS(SDS)LUM-201 (3.2 mg/kg/Day)
Mean0.9343 ± 1.1716
08

Study locations

10 sites
  • Rady Children's Hospital
    San Diego, California 92123, United States
  • Children's National Hospital
    Washington D.C., District of Columbia 20010, United States
  • Indiana University School of Medicine
    Indianapolis, Indiana 46202, United States
  • M Health, Fairview Pediatric Specialty Clinics- Discovery Clinic
    Minneapolis, Minnesota 55454, United States
  • The Children's Mercy Hospital
    Kansas City, Missouri 64111, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • Klinika Endokrynologii i Chorob Metabolicznych, Instytut Centrum Zdrowia Matki Polki
    Lodz, Poland
  • Sonomed - Centrum Medyczne
    Szczecin, Poland
  • Klinika Endokrynologii i Diabetologii, Instytut "Pomnik Centrum Zdrowia Dziecka
    Warsaw, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Jan 2025, 35 months.

Results were first posted in Apr 2026, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2022
First posted
Feb 22, 2022
StartActual
Feb 18, 2022
Primary completionActual
Jan 22, 2025
CompletionActual
Jan 22, 2025
Results first posted
Apr 13, 2026
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05250063
Lead sponsor
Lumos Pharma
Responsible party
Sponsor
First posted
Feb 22, 2022
Start date
Feb 18, 2022
Primary completion
Jan 22, 2025
Completion
Jan 22, 2025
Results posted
Apr 13, 2026
Last update
May 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibutamoren

Start the discussion